Blog

$Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved – NCI Center for Cancer Research$

Photo of Ira Pastan from federalnewsnetwork.com

Sep 26, 2024, 11:19

Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved – NCI Center for Cancer Research

NCI Center for Cancer Research shared a post on LinkedIn:

“BREAKTHROUGH IN TREATMENT: In 2012, Senior Investigator Ira Pastan, M.D., tested the immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia (HCL).

As a result, the drug is now an FDA approved therapy for the disease if it has recurred or progressed after at least two prior systemic therapies.

cancer cancer awareness Cancer research FDA fight against cancer Global fight against cancer Hairy Cell Leukemia HCL Ira Pastan NCI NCI Center for Cancer Research OncoDaily Oncology

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Special Coverage